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Nontyphoidal Salmonella (NTS), particularly Salmonella enterica serovars Typhimurium and Enteritidis, is responsible for a
major global burden of invasive disease with high associated case-fatality rates. We recently reported the development of a can-
didate O-antigen–CRM197 glycoconjugate vaccine against S. Typhimurium. Here, using a panel of mouse monoclonal antibodies
generated by the vaccine, we examined the relative efficiency of different antibody isotypes specific for the O:4 antigen of S. Ty-
phimurium to effect in vitro and in vivo killing of the invasive African S. Typhimurium strain D23580. All O:4-specific antibody
isotypes could mediate cell-free killing and phagocytosis of S. Typhimurium by mouse blood cells. Opsonization of Salmonella
with O:4-specific IgA, IgG1, IgG2a, and IgG2b, but not IgM, resulted in cell-dependent bacterial killing. At high concentrations,
O:4-specific antibodies inhibited both cell-free complement-mediated and cell-dependent opsonophagocytic killing of S. Typhi-
murium in vitro. Using passive immunization in mice, the O:4-specific antibodies provided in vivo functional activity by de-
creasing the bacterial load in the blood and tissues, with IgG2a and IgG2b being the most effective isotypes. In conclusion, an
O-antigen–CRM197 glycoconjugate vaccine can induce O-antigen-specific antibodies of different isotypes that exert in vitro and
in vivo killing of S. Typhimurium.
Invasive nontyphoidal Salmonella (iNTS) disease predominatelymanifests as bacteremia in sub-Saharan Africa and is most com-
monly caused by Salmonella enterica serovars Typhimurium and
Enteritidis (1–3). With case-fatality rates of 20 to 25% in children
(1) and up to 47% in HIV-infected adults (4), iNTS disease rep-
resents a major global health burden. Many African NTS isolates
are multidrug resistant (5, 6), making iNTS disease difficult to
manage. There is currently no vaccine against NTS for use in hu-
mans.
The presence of specific antibodies (Abs) against the O antigen
of lipopolysaccharides (LPS), in addition to the outer membrane
proteins and flagellar protein, has been well documented in re-
sponse to Salmonella infection (7, 8). O antigen forms the distal
portion of LPS and is a component of the outer membrane of
Gram-negative bacteria. NTS bacteria that do not express O anti-
gen are avirulent (9, 10). Due to the surface location of the O
antigen and the almost universal presence of this antigen among
pathogenic Salmonella strains, there is much interest in the poten-
tial of O antigen as a vaccine candidate (11). Immunization with
experimental Salmonella O-antigen conjugate vaccines can effect
in vivo killing of S. Typhimurium following an intraperitoneal
challenge (12).
To address the need for a vaccine against iNTS disease, we
recently developed a candidate S. Typhimurium O-antigen–
CRM197 glycoconjugate vaccine using O antigen from the invasive
African S. Typhimurium isolate D23580 (13). Initial studies with
our vaccine indicated good immunogenicity in mice. Vaccination
induced high levels of antibodies with cell-free bactericidal activity
against D23580 (13).
Bactericidal antibody has the potential to protect against iNTS
disease in Africans (14), and serum bactericidal assays (SBAs) have
been used to gauge in vitro activity of naturally induced antibodies
against Salmonella in Africans and Asians (14, 15). The role of
antibodies in phagocyte-mediated immunity against Salmonella
has been demonstrated in various studies in mice (16, 17), and
antibodies are regarded as having a key role in immunity to Sal-
monella infection (18, 19). Antibody opsonizes Salmonella for up-
take into phagocytes, resulting in intracellular killing of the bac-
teria, and is essential for phagocytosis and intracellular killing in
both mouse and human macrophages (20–22). Blood cells, in the
presence of opsonizing antibody and complement, can mediate
phagocytosis and kill African Salmonella isolates (21).
In this study, we investigate the potential efficacy and mecha-
nisms of antibody-dependent killing induced by an S. Typhimu-
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rium O:4,5-CRM197 glycoconjugate vaccine against iNTS disease.
We examine the in vitro cell-free and cell-dependent functions of
the vaccine-induced antibodies and in vivo killing of Salmonella
following passive transfer and S. Typhimurium challenge. At high
concentrations, O-antigen-specific antibodies from African
adults are associated with impaired serum killing of S. Typhimu-
rium and can directly inhibit bacterial killing by serum from
healthy adults (23, 24). We therefore also examine the ability of
O-antigen-specific monoclonal antibodies to inhibit Salmonella
killing.
MATERIALS AND METHODS
Ethical approval. Ethical approval for the use of serum samples in this
study was granted by the Life and Health Sciences Ethical Review Com-
mittee of the University of Birmingham. Informed written consent was
obtained from participants. The care and use of all mice were in accor-
dance with United Kingdom Home Office regulations (United Kingdom
Animals Scientific Procedures Act 1986). The mice were maintained un-
der specific-pathogen-free conditions and matched by age and sex within
experiments.
Bacterial isolates. Salmonella isolates were S. Typhimurium D23580,
S. Typhimurium LT2, S. Typhimurium SL1344, S. Enteritidis D24954, S.
Enteritidis SL7488, S. Senftenberg 20050439, and S. Agona 20071186.
D23580, multilocus sequence type (MLST) ST313, is an invasive African
isolate of NTS from Blantyre, Malawi, and is representative of most inva-
sive NTS isolates in Malawi since 2002 (14, 25, 26). LT2 and SL1344 are
commonly used S. Typhimurium laboratory isolates previously described
by Hoiseth and Stocker (27). D23580 and LT2 express O:1, -4, -5, and -12.
D23580 also expresses O acetylation on C-2/C-3 in the rhamnose residues
(13, 28). D24954 is an invasive S. Enteritidis isolate from Blantyre, which
expresses O:1, -9, and -12. SL7488 is a mutant Thirsk isolate expressing
O:4 in place of O:9, in addition to O:1 and O:12 (29). 20050439 expresses
O:1, -3, and -19, while 20071186 expresses O:4 and O:12 (30).
O-antigen-specific monoclonal antibodies. The generation of the
O-antigen-specific monoclonal antibodies was performed by Absea Bio-
technology Ltd. (Beijing, China). Briefly, mice were immunized subcuta-
neously with two 8-g doses of S. Typhimurium D23580 O-antigen–
CRM197 glycoconjugate (with Freund’s complete adjuvant) on days 0 and
21 and another 8-g dose of glycoconjugate (with Freund’s incomplete
adjuvant) on day 42. On day 56, mice were boosted intravenously (i.v.)
with 8 g of the glycoconjugate. The mice were killed 3 days later, and
their spleens were processed for cell fusion to generate hybridomas. O-an-
tigen-specific antibody-secreting hybridomas were screened by Absea us-
ing S. Typhimurium O-antigen enzyme-linked immunosorbent assay
(ELISA), where O-antigen-specific antibody was detected by goat anti-
mouse Ig alkaline phosphatase (AP)-conjugated antibodies (Sigma, Mi-
lan, Italy).
Positive hybridoma lines were subcloned to obtain single clonal pop-
ulations of hybridomas with each clonal population secreting antibody of
the same specificity. Following subcloning, O-antigen-specific hybrid-
omas were first screened using O-antigen ELISA by Absea and then fur-
ther screened at the Novartis Vaccines Institute for Global Health
(NVGH) for antibody binding to S. Typhimurium using flow cytometry
and bacterial agglutination. To ensure that monoclonal antibodies were
specific for S. Typhimurium O antigen, we analyzed the antibody binding
to six different Salmonella isolates (Table 1) by flow cytometry (see be-
low). Flow cytometric data were verified by bacterial agglutination with
the six bacterial isolates using the same selection criteria shown in Table 1.
The antibody isotypes of the selected antibody-secreting clones were also
characterized using a mouse isotyping kit (Sigma). Five O-antigen-spe-
cific antibody-secreting clones, of different isotypes, were chosen (IgA,
IgM, IgG1, IgG2a, and IgG2b). We included a mouse nonspecific IgG2a
isotype monoclonal antibody (eBiosciences, Hatfield, United Kingdom)
as a control.
Anti-O-antigen antibody binding assay. For the screening of O-an-
tigen-specific hybridomas, salmonellae in log growth phase were incu-
bated with the hybridoma culture supernatants at a final bacterial concen-
tration of 2 108/ml. Antibodies bound to the bacteria were detected with
fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG, IgA,
and IgM antibody (Sigma) (14). Samples were read on a FACSCanto
instrument, and data were analyzed using FlowJo. The mean geometric
fluorescence in the FL1 channel was used to indicate anti-Salmonella an-
tibody levels. The percentage of bacteria that are bound by anti-O-antigen
antibody was determined from the FL1 channel (14).
Kd analysis of O-antigen-specific antibodies. The avidity of purified
O-antigen-specific antibodies binding to S. Typhimurium O antigen was
assessed using a Biacore 3000 system (GE Healthcare, Buckingham,
United Kingdom) (23). O antigen was immobilized on a hydrophobic
HPA sensor chip (GE Healthcare). The chip was washed with wash buffer
(100 mM sodium chloride containing 10 mM HEPES buffer, pH 7.4),
followed by two washes with 40 mM n-octyl glucoside (Sigma). The chip
was coated with 1 mg/ml O antigen by passing O antigen across the chip
surface for 30 min at a flow rate of 2 l/min. The chip was then washed
with 0.1 M hydrochloric acid and blocked with 0.1 mg/ml bovine serum
albumin (BSA). After coating, the chip was washed using two injections of
0.1 M hydrochloric acid and left in 0.1 M hydrochloric acid for 2 min.
Each O-antigen-specific antibody isotype was 2-fold serially diluted to
generate a series of eight dilutions in wash buffer (100, 50, 25, 12.5, 6.25,
3.125, 1.56, and 0.78 nM) and then passed across the chip surface for 10
min at a flow rate of 5 l/min. The chip was left in the antibody solution
for 10 min and then washed with a continuous flow of wash buffer for
another 10 min at a rate of 5 l/min. The chip surface was regenerated
with 0.1 M hydrochloric acid. Antibody binding was measured by observ-
ing the change in the surface plasmon resonance (SPR) angle of the O
antigen bound to the chip for each of antibody dilutions. Kd (dissociation
constant) values were calculated by fitting the binding curves to the one-
site binding (hyperbola) model (chosen as it gave the best fit) using the
BiaEvaluation software (Biacore; GE Healthcare) and GraphPad Prism.
Human complement. Normal human serum contains Salmonella-
specific antibodies (14, 31). To use the serum as an exogenous source of
complement, we depleted serum obtained from healthy HIV-uninfected
TABLE 1 Selection criteria for monoclonal O-antigen antibodies
Antibody specificity
Binding to Salmonella isolate:
S. Typhimurium
D23580,
O:1,4,5,12
S. Typhimurium
LT2,
O:1,4,5,12
S. Enteritidis
D24954,
O:1,9,12
S. Enteritidis
SL7488,
O:1,4,12
S. Senftenberg
20050439,
O:1,3,19
S. Agona
20071186,
O:4,12
O:1      
O:4      
O:5      
O:9      
O:12      
23 subcloned monoclonal Abs      
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adult volunteers, with no known history of Salmonella disease, of these
antibodies by adsorption with Salmonella. Briefly, bacteria were washed
with phosphate-buffered saline (PBS) and prechilled to 4°C before being
added to freshly thawed serum at a final concentration of 5 109/ml. The
suspension was incubated at 4°C for 30 min, after which the bacteria were
removed by centrifugation. The serum underwent two more cycles of
incubation with the same amount of fresh bacteria. It was then sterilized
through a 0.22-m filter and used immediately. As human complement
was found to be the only complement source able to mediate bacterial
killing in both the SBA and the blood cell killing assays, it was used as the
complement source for all subsequent assays.
Serum bactericidal assay. Bacteria in log growth phase were incu-
bated with O-antigen-specific antibodies and exogenous complement (ei-
ther baby rabbit serum [BRS] [31] or Salmonella-specific antibody [Ab]-
depleted human serum). Numbers of viable salmonellae were determined
after 180 min. BRS was obtained from AbD Serotec (Kidlington, United
Kingdom). For SBA examining the inhibition of serum bactericidal activ-
ity, bacteria were incubated with O-antigen-specific antibody and 50%
normal human serum, which effects a 2-log10 kill at 180 min after serum
exposure (14).
Blood cell killing assay. Killing of Salmonella by RPMI-washed pe-
ripheral blood cells was determined in a blood cell killing assay. The assay
has been adapted from one previously described using human blood cells
from healthy HIV-uninfected adults (21) for use with mouse antibodies
and mouse blood cells isolated from naive C57BL/6 mice (Harlan, United
Kingdom). Bacteria were opsonized with O-antigen-specific antibodies
and exogenous complement (either BRS, naive mouse serum, or Ab-de-
pleted human serum) at a 75% final volume for 20 min at room temper-
ature at a final bacterial concentration of 106/ml. Under these conditions,
cell-free killing of S. Typhimurium does not occur. Opsonized salmonel-
lae were added to washed blood cells at a multiplicity of infection (MOI)
of 1:1 (final bacterial concentration of 105/ml). After 180 min, the cells
were lysed with 0.1% Triton X (Sigma) and numbers of viable bacteria
were determined. For blood cell killing assays examining the inhibition of
bacterial killing, bacteria were opsonized with O-antigen-specific anti-
bodies (over a higher concentration range), Ab-depleted human serum,
and 1:64-diluted S. Typhimurium-specific mouse immune serum, which
gives a 1-log10 kill in a 180-min blood cell killing assay.
Phagocytosis assay. FITC-labeled bacteria were first opsonized with
O-antigen-specific antibodies and Ab-depleted human serum for 20 min
at room temperature at a final concentration of 109/ml (21) or 106/ml. The
opsonized salmonellae were added to precooled blood cells (all blood
cells; final blood cell concentration of 105/ml) at an MOI of 1,000:1 or 1:1
(final bacterial concentration of 108/ml or 105/ml, respectively) and incu-
bated at 37°C for 10 min. Trypan blue (0.16%; Sigma) was added to each
sample to quench the fluorescence of noninternalized bacteria. Cells were
resuspended in fluorescence-activated cell sorting (FACS) lysing solution
(BD Biosciences, Oxford, United Kingdom). Samples were read on a
FACSCanto flow cytometer (BD Biosciences), and data were analyzed
using FlowJo. The percentage of blood cells that had phagocytized salmo-
nellae was determined from the FL1 channel.
Mouse infection. Six- to eight-week-old female Nramp/ C57BL/6
mice (Harlan, United Kingdom) were used. Six groups of six mice were
passively transferred with 0.1 mg antibodies i.v.: the five different O-an-
tigen-specific antibody isotypes and a nonspecific isotype control anti-
body (IgG2a). At 24 h following passive transfer of antibodies, the six
groups of mice were challenged with 107 D23580 cells i.v. (equivalent to
0.5  107/ml as a mouse has 2 ml of blood). A high inoculum was
necessary to examine blood clearance, as only a small blood volume could
be taken at each time point in order to minimize reaction due to blood
loss. In vivo killing of Salmonella was measured by blood clearance and
bacterial loads in the liver and spleen. Mice were bled at time points 15, 30,
60, and 360 min postchallenge to assess blood clearance of bacteria. At 24
h postchallenge, the mice were killed. Spleens and livers were homoge-
nized in water using a Colworth stomacher (West Sussex, United King-
dom). Viable bacterial counts in blood, spleens, and livers were deter-
mined by LB agar plating.
Statistical methods. Comparisons of data from different groups of
mice were performed using the Mann-Whitney U test, with a P value of
0.05 considered to be significant.
RESULTS
O-antigen-specific monoclonal antibodies. Mice were immu-
nized with the S. Typhimurium D23580 O-antigen–CRM197 vac-
cine. Using ELISA, 103 out of 2,400 (4.3%) hybridomas were
found to secrete antibodies against O antigen. These were further
screened for binding to live S. Typhimurium by agglutination and
flow cytometry, leading to the selection of 25 hybridomas for sub-
cloning. Twenty-three of the 25 (92%) hybridomas were success-
fully cloned, and we screened their supernatants for antibody
binding to different Salmonella strains. Using the criteria shown in
Table 1, we determined the O-antigen specificity of the 23 mono-
clonal antibodies. All were found to be specific for the O-antigen
factor 4 (O:4), which is expressed by Salmonella group B isolates,
including S. Typhimurium. A final panel of five monoclonal an-
tibodies was selected for use in this study, each having a different
isotype—IgA, IgM, IgG1, IgG2a, and IgG2b. High-pressure liquid
chromatography (HPLC)–size exclusion chromatography (SEC)
and SDS-PAGE indicated that most of the IgA monoclonal anti-
body was in monomeric form with a minority present as dimers
(data not shown).
Avidity of O-antigen-specific antibodies. We determined the
avidity of the five O:4-specific monoclonal antibodies by SPR. The
Kd values of the five antibody isotypes are shown in Table 2. All five
monoclonal antibodies have high avidities in the 15 to 60 nM
range, with the IgM antibody having the highest avidity.
Cell-free bactericidal potential of O-antigen-specific anti-
bodies. We examined the cell-free bactericidal potential of the
O:4-specific antibodies against S. Typhimurium D23580 and
SL1344 by SBA, using either 75% BRS (31) or human complement
as an exogenous complement source.
All five antibody isotypes showed cell-free bactericidal activity
against D23580 (Fig. 1A and C) and SL1344 (Fig. 1B and D),
although there was a lack of bactericidal activity at high antibody
concentrations. The bactericidal antibodies included IgA and
IgG1 isotypes, which have been reported not to be able to fix
complement (32, 33). These data confirm that O:4-specific anti-
bodies have bactericidal potential against S. Typhimurium, con-
sistent with our previous data on antibody raised to S. Typhimu-
rium D23580 O antigen (34) and extracted O-antigen-specific
antibodies from African adults and healthy adults in the United
States (35, 36).
Blood phagocyte killing mediated by O-antigen-specific an-
tibodies. The ability of the O:4-specific monoclonal antibodies to
mediate killing of D23580 and SL1344 by blood phagocytes was
examined. Bacteria were opsonized for 20 min at room tempera-
TABLE 2 Avidity of O-antigen-specific monoclonal antibodies
Isotype Kd SE (nM)
IgA 60.42 5.29
IgM 14.73 0.60
IgG1 54.82 6.30
IgG2a 58.01 6.76
IgG2b 25.65 4.34
Goh et al.
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ture with the monoclonal antibodies and exogenous complement
(conditions under which cell-free killing of S. Typhimurium does
not occur) prior to incubation with peripheral mouse blood cells.
We confirmed that the bacteria were opsonized by each of the
antibody isotypes by examining antibody binding (Fig. 2A and B)
using flow cytometry.
With 75% BRS as the complement source for opsonization,
there was no blood cell killing of either D23580 or SL1344 (Fig. 3A
and B), suggesting that BRS is not an appropriate complement
source for in vitro bacterial killing by mouse antibodies and blood
cells. When the complement source was 75% naive mouse serum
(Fig. 3C and D), we observed an1-log10 kill of both isolates with
IgA, IgG1, IgG2a, and IgG2b, despite a lack of killing at high an-
tibody concentrations. IgM was unable to mediate bacterial killing
by blood cells. With Ab-depleted human serum as complement
source (Fig. 3E and F), again, O:4-specific IgA, IgG1, IgG2a, and
IgG2b, but not IgM, could effect blood cell killing of Salmonella.
These findings demonstrate that O-antigen-specific antibodies are
able to mediate bacterial killing by blood phagocytes and reveal
the isotype dependency of this.
Impact of high concentration of O-antigen-specific antibod-
ies on cell-free bactericidal activity and phagocyte killing of Sal-
monella. Next, we examined whether high concentrations of the
monoclonal antibodies could inhibit the killing of Salmonella by
serum from healthy adults. All five monoclonal antibodies com-
pletely inhibited normal serum killing of D23580 (Fig. 4A) and
SL1344 (Fig. 4B) at concentrations above 62.5 g/ml. This inhi-
bition occurred with all antibody isotypes.
We then examined whether the monoclonal antibodies could
inhibit cell-dependent killing of S. Typhimurium by immune
mouse serum. Immune mouse serum was diluted 1/64 and used to
opsonize salmonellae, since it can effect blood cell killing of
FIG1 Cell-free killing of S. Typhimurium by O-antigen-specific antibodies. SBAs were performed with either BRS (A and B) or Ab-depleted human (Hu) serum
(C and D) as a complement source. Target bacterial isolates were D23580 (A and C) and SL1344 (B and D). Mouse nonspecific IgG2a isotype was included as a
control.
FIG 2 Binding of O-antigen-specific antibody on S. Typhimurium following opsonization. The percentage of O-antigen-specific antibody-bound S. Typhimu-
rium D23580 (A) and SL1344 (B) following opsonization was determined by FITC-conjugated goat anti-mouse Ig antibody using flow cytometry.
O-Antigen Monoclonal Antibody Killing of Salmonella
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D23580 and SL1344 by 1 log10 at this concentration (Fig. 5), to-
gether with human complement and a range of concentrations of
purified O:4-specific antibodies. All O-antigen-specific antibodies
inhibited cell-dependent killing of D23580 (Fig. 4C) and SL1344
(Fig. 4D) at concentrations of 8 g/ml and above.
Phagocytosis of Salmonella opsonized with O-antigen-spe-
cific antibodies. We examined the ability of the O:4-specific
monoclonal antibodies to mediate phagocytosis. When the bacte-
ria were opsonized at a bacterial concentration of 109/ml and
added to washed blood cells (all blood cells) at 108 bacteria/ml
(MOI of 1,000:1; final blood cell concentration of 105/ml; final
bacterial concentration of 108/ml), we observed efficient bacterial
uptake with all isotypes of the monoclonal antibodies, with 80 to
90% of the blood cells phagocytizing bacteria opsonized with an-
tibody at a concentration of 250 g/ml and then gradually de-
creasing to levels comparable to those mediated by the control
isotype at antibody concentrations of 0.24 g/ml (Fig. 6A and B).
Similar phagocytosis profiles were obtained with D23580 and
SL1344.
We then repeated the phagocytosis assay, using bacteria op-
sonized at a concentration of 106/ml and added to washed blood
cells (all blood cells) at 105 bacteria/ml (MOI of 1:1; final blood cell
concentration of 105/ml; final bacterial concentration of 105/ml),
as used in the blood cell killing assay. For both D23580 and
SL1344, the maximal percentage of blood cells with phagocytized
bacteria was 30% and occurred when opsonized using all iso-
types of O-antigen-specific antibodies at concentrations of 3.9 to
0.24 g/ml (Fig. 6C and D). When high antibody concentrations
of 250 to 16 g/ml were used to opsonize the bacteria, in contrast
to findings with 109/ml bacteria, the percentage of blood cells with
phagocytized bacteria was greatly reduced using a bacterial con-
centration of 106/ml.
In vivo killing of Salmonella mediated by O-antigen-specific
antibodies. Using passive immunization, we investigated the abil-
ity of the O:4-specific monoclonal antibodies to kill Salmonella
following systemic infection. All O:4-specific monoclonal anti-
bodies mediated blood clearance efficiently, with the bacterial
load over 2 log10 lower than with the control isotype antibody by
the first time point at 15 min after bacterial challenge (Fig. 7).
There was a further gradual decrease in the bacterial load between
15 and 60 min postchallenge. At 60 and 360 min postchallenge, the
mice receiving the O:4-specific IgG2a and IgG2b antibodies had
the lowest bacterial load. As mouse complement has limited bac-
tericidal ability (37), the decrease in the bacterial load is likely to
FIG 3 Blood cell killing of S. Typhimurium opsonized with O-antigen-specific antibodies and complement. Viable bacteria were opsonized with a mix of
O-antigen-specific antibodies and BRS (A and B), naive mouse serum (C and D), or Ab-depleted human serum (E and F). Target bacterial isolates were D23580
(A, C, and E) and SL1344 (B, D, and F). Mouse nonspecific IgG2a isotype was included as a control.
Goh et al.
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result from bacterial uptake and bacterial killing by blood phago-
cytes and splenic macrophages.
At 24 h postinfection, mice receiving the O:4-specific IgA, IgG2a,
and IgG2b (P  0.05), but not IgM and IgG1, had lower bacterial
loads in the liver (Fig. 7G) compared with the control isotype by
approximately 0.5 log10. Passive transfer of all isotypes of the O:4-
specific antibodies resulted in lower bacterial load in the spleen (P
0.05) (Fig. 7H) compared with the control isotype by around 1.0
log10. IgG2a and IgG2b were the most efficient, with the lowest bac-
terial numbers compared to the other isotypes (P 0.05).
DISCUSSION
O antigen is a principal target of the protective humoral responses
against Salmonella (12, 29, 36, 38). Here, we have investigated the
in vitro and in vivo killing and potential of the antibody response
elicited by an S. Typhimurium O:4,5-CRM197 vaccine using
monoclonal antibodies generated following immunization, with
differing isotypes but all specific for the O:4 antigen of S. Typhimu-
rium.
The first key finding is that antibodies specific to the O:4 anti-
gen can effect cell-free serum killing of Salmonella and efficiently
opsonize Salmonella for phagocytosis and bacterial killing by blood
immune cells in vitro. These antibodies could also mediate in vivo
killing following a virulent challenge of S. Typhimurium through
blood clearance and reduced bacterial load in the spleen and liver.
This is particularly important, since NTS bacteremia represents a ma-
jor disease burden in Africa with high case-fatality rates (1, 4).
A previous study by Carlin et al. found that IgG1 and IgG3
FIG 4 Inhibition of normal serum bactericidal activity and blood cell killing of S. Typhimurium by O-antigen-specific antibodies. Inhibition of serum killing of
D23580 (A) and SL1344 (B) was examined in an inhibition SBA, where bacteria were incubated with different concentrations of O-antigen-specific antibodies
and 50% normal human serum. Inhibition of blood cell killing of D23580 (C) and SL1344 (D) was examined in an assay of inhibition of blood cell killing, where
bacteria were first opsonized with different concentrations of O-antigen-specific antibodies and mouse S. Typhimurium-immune serum at a 1/64 dilution.
FIG 5 Blood cell killing of Salmonella mediated by naive and S. Typhimurium-immune mouse serum. Viable S. Typhimurium D23580 (A) and SL1344 (B) were
opsonized with a mix consisting of Ab-depleted human serum and either naive mouse serum or S. Typhimurium-immune serum. Blood cells were incubated
with the opsonized Salmonella at an MOI of 1:1 (final concentration of bacteria at 105/ml). After 180 min, the cells were lysed and numbers of viable bacteria were
determined by serial dilution with plating on LB agar.
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monoclonal antibodies directed against the O:4 epitope of S. Ty-
phimurium were potent at protecting mice against a 50% lethal
dose (LD50) intraperitoneal challenge with S. Typhimurium SH
2201 (38). IgG3 monoclonal antibodies to the O:12 epitope were
much less effective. Since, in the current study, mice were chal-
lenged with the invasive African S. Typhimurium STS313 isolate
D23580, our data help demonstrate the potential effectiveness of
an S. Typhimurium O-antigen glycoconjugate vaccine for Africa.
The lower reduction of bacterial numbers in the liver and spleen
compared with that found in the blood may reflect the distribu-
tion of antibody in the body posttransfer and the half-life of the
antibodies in these tissues.
The second key finding relates to the isotype dependency of
O:4-specific antibodies able to mediate these in vitro and in vivo
activities. Cell-free killing of S. Typhimurium was not isotype de-
pendent. Since we have found that O-antigen-specific IgA in the
blood of African adults does not have bactericidal activity (23), it
is somewhat surprising that the mouse O-antigen-specific IgA can
kill S. Typhimurium. It is plausible that IgA antibody from differ-
ent species does not activate complement to the same degree. Pre-
viously, IgA has been reported to activate the alternative pathway
(39, 40) and the mannose-binding lectin pathway of complement
(41), suggesting a possible mechanism for the bactericidal activity
that we observed in the study. The study by Carlin et al. (38) found
that IgA monoclonal antibodies to S. Typhimurium O antigen did
not fix complement and were not protective, but these were di-
rected against the O:5 epitope, rather than the O:4 epitope.
Mouse anti-Brucella IgA and antihapten IgG1 have been re-
ported to be incapable of fixing complement (32, 42). This could
depend on the exact target of the antibody, or an O-antigen gly-
coconjugate vaccine may induce IgA and IgG1 with bactericidal
potential, where natural exposure to Salmonella does not. For ex-
ample, mouse transferrin-binding protein B-specific IgG1 has
been reported to have bactericidal activity against Neisseria men-
ingitidis (43). A study that examined the complement-fixing abil-
ity of mouse IgG antibodies targeting various antigens found six
out of 17 mouse IgG1 antibodies able to activate complement
efficiently (44).
In vitro cell-dependent killing of S. Typhimurium was isotype
dependent, with IgM being unable to effect killing. However, all
O:4-specific antibody isotypes were able to mediate phagocytosis
with similar efficiencies. This apparently paradoxical finding
could be due to alternative trafficking pathways in relation to
phagolysosome fusion. In-depth studies to examine downstream
signaling mediated by IgM Fc receptors could help clarify this. In
addition to the polymeric Ig receptors that are mainly expressed
by epithelial cells in the mucosal lumen (45), there are other IgM
Fc receptors, Fc	/R (46) and FcR (47), which are also ex-
pressed by immune cells in the bloodstream. Fc	/R has been
reported to mediate phagocytosis of IgM-opsonized Staphylococ-
cus aureus by B cells (46), while the recently identified FcR has
been suggested to serve as an uptake receptor for IgM-opsonized
particles by B cells (47).
NTS carriage in asymptomatic individuals has been reported in
Africa (48) and could constitute a reservoir for community-ac-
quired NTS bacteremia in children (48). It is possible that NTS
takes advantage of the inefficiency of IgM-mediated intracellular
killing by blood immune cells to escape into the intracellular
niche, where it has adapted to survive and can avoid antibody-
dependent complement-mediated killing.
In vivo killing by the monoclonal antibodies following chal-
lenge with Salmonella was also isotype dependent. All O:4 anti-
body isotypes lowered bacterial loads in vivo. Despite the lack of
killing in the in vitro blood cell killing assay, IgM lowered the
FIG 6 Phagocytosis of S. Typhimurium opsonized with O-antigen-specific antibodies and complement. FITC-labeled bacteria were opsonized with a mix of
O-antigen-specific antibodies and Ab-depleted human serum at a final concentration of 109 bacteria/ml (A and B) or 106 bacteria/ml (C and D). Opsonized
D23580 (A and C) or SL1344 (B and D) was added to precooled blood cells at an MOI of 1,000:1 or 1:1 (final concentration of bacteria at 108/ml or 105/ml,
respectively). The percentage of blood cells that had phagocytized salmonellae was determined by flow cytometry.
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blood bacterial load in mice, possibly because IgM-mediated
phagocytosis is as efficient as phagocytosis following opsonization
with the other antibody isotypes. In the spleen, a lower bacterial
load was observed with IgM than with the control isotype, which
could be attributed to the different cell types involved, with IgM-
mediated bacterial killing being more efficient in splenic macro-
phages than blood phagocytes. It is also plausible that there is
more efficient bacterial killing mediated by IgM in the spleen, as it
contains more B cells, than in peripheral blood, in which IgM
receptors are found in greater abundance (46, 47).
IgM did not lower the bacterial load in the liver, and the reduc-
tion in bacterial load in the spleen was lowest following passive
transfer with IgM, compared with the other monoclonal antibody
isotypes. This suggests that IgM is less efficient in mediating in vivo
protection than the other immunoglobulin isotypes. However, in
the study by Carlin et al., IgM monoclonal antibodies to O:4,12
and O:12 were protective against the S. Typhimurium LD50 chal-
lenge (38). The difference in findings with IgM antibodies in the
two studies may relate to differences in the challenge models used
and differences in the specificities of the antibodies.
IgG2a and IgG2b in the current study were consistently the
most efficient isotypes at lowering bacterial loads in the blood,
liver, and spleen. This is likely because IgG2a and IgG2b efficiently
bind to Fc
 receptors, particularly Fc
RI, with high affinity (49).
We have previously demonstrated that human IgG1 and IgG3 are
more efficient in mediating intracellular S. Typhimurium killing
in vitro (20). The production of IgG2a and IgG2b in mouse and
IgG1 and IgG3 in human is upregulated by Th1 cytokines such as
gamma interferon (IFN-
) (50–52). Vaccine formulation and re-
gimes that induce human Th1 responses resulting in a predomi-
nantly IgG1 and IgG3 antibody response could therefore be most
effective in conferring protection against NTS.
The third key finding of the study is that there is an optimal
range of O-antigen antibody concentration, beyond which in vitro
killing activity against NTS is lost. Our phagocytosis data suggest
that the in vitro opsonic function of antibody is dependent on the
quantity of bacteria and the ratio of antibody to bacteria. The
difference in the maximal percentage of blood cells with phagocy-
tized bacteria in the two assays could be attributable to the differ-
ence in the MOIs. With a higher MOI, the maximal percentage of
blood cells with phagocytized bacteria is likely to be higher. In
addition, no O:4-specific antibody isotype was able to effect cell-
FIG 7 In vivo killing of Salmonella in mice following passive immunization with O-antigen-specific monoclonal antibodies and bacterial challenge. Bacterial
loads in blood (A to F), liver (G), and spleen (H) were determined 24 h postchallenge in mice that were given 0.1 mg antibodies i.v., either control IgG2a
antibodies (A) or IgA (B), IgM (C), IgG1 (D), IgG2a (E), or IgG2b (F) isotypes of the O-antigen-specific antibody 24 h before bacterial challenge. Each point in
graphs A to F represents the mean log10 bacterial count standard deviation (n 6), while each point in graphs G and H represents one mouse (n 6), with
the line representing mean log10 bacterial counts in each group of mice. *, P value of0.05.
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free bacteriolysis and cell-dependent bacterial killing at high anti-
body concentrations. When added to normal human serum and
mouse immune serum at high concentrations, all O:4 antibody
isotypes inhibited cell-free bacteriolysis and cell-dependent killing
of Salmonella, respectively.
These data are consistent with our previous work on S. Typhi-
murium O-antigen-specific IgG antibodies from HIV-infected
and HIV-uninfected African adults (23, 24) and recent studies on
the IgG2 antibodies against the O antigen of Pseudomonas aerugi-
nosa in patients with bronchiectasis (53). This loss of activity has
been called a prozone effect and is an established phenomenon
(54). Similar effects have been reported in the past, where passive
transfer of high levels of specific antibodies has resulted in lack of
protection against subsequent challenge with other pathogens, in-
cluding pneumococcus (55) and Cryptococcus neoformans (54).
Despite the in vitro inhibition observed in the current study, the
O:4-specific antibodies were found to kill Salmonella in vivo, low-
ering the bacterial loads in blood, liver, and spleen, although only
one dose of antibody was used. How these findings would impact
the effectiveness of an O-antigen-based vaccine against iNTS for
Africa is uncertain and will be answered only by appropriate clin-
ical trials.
In conclusion, the O-antigen glycoconjugate candidate vaccine
can induce antibodies that effect in vivo cell-free bacteriolysis and
cell-dependent bacterial killing against S. Typhimurium, with ef-
ficient in vivo killing of Salmonella in mice, providing support for
the idea that an O-antigen glycoconjugate vaccine is a promising
vaccine approach against NTS.
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